JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Modifying risk factors to prevent and treat erectile dysfunction.

INTRODUCTION: Erectile dysfunction (ED) is a common complaint in men over 40 years of age and prevalence rates increase with age. Comorbidities such as heart disease, diabetes, dyslipidemia, hypertension, and depression have been described as primary risk factors for the development of ED. Additionally, a number of modifiable lifestyle factors, including physical activity, smoking, alcohol consumption, diabetes control, and obesity, have been associated with ED.

AIM: The association of modifiable behavioral factors with ED, mainly among men without recognized comorbidities, opens the possibility for intervention strategies to prevent and potentially improve erectile function in patients suffering with ED.

CONCLUSION: While intriguing, most of the literature and evidence is not completely scientifically compelling as to how modifying lifestyle risk factors can improve erectile function. Weight loss may reverse ED through other mechanisms, namely, decreased inflammation, increased serum testosterone levels, and improved mood and self-esteem. Currently, the evidence at hand recommends that patient education should be aimed at increasing exercise, reducing weight to achieve a body mass index less than 30 kg/m(2), and stopping smoking to improve or restore erectile function, mainly in men without established comorbidities. When comorbidities are present, lifestyle modifications may be important in preventing or reducing sexual dysfunction. These modifications may include precise glycemic control in diabetic men and the use of pharmacologic therapies for hypertension and depression, which are less likely to cause sexual side effects.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app